Gotham Asset Management LLC Has $14.25 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Gotham Asset Management LLC lifted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 41.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 427,855 shares of the biotechnology company's stock after buying an additional 126,375 shares during the quarter. Gotham Asset Management LLC owned about 0.15% of Exelixis worth $14,248,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of EXEL. Coppell Advisory Solutions LLC acquired a new position in Exelixis during the 4th quarter valued at $25,000. Colonial Trust Co SC raised its stake in Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 765 shares during the last quarter. USA Financial Formulas acquired a new position in Exelixis during the 4th quarter valued at $32,000. Principal Securities Inc. raised its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 373 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new position in Exelixis during the 4th quarter valued at $39,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXEL has been the subject of several research analyst reports. StockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Stephens reiterated an "equal weight" rating and set a $29.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Citigroup reissued an "outperform" rating on shares of Exelixis in a report on Wednesday. Finally, Oppenheimer lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $41.00 to $33.00 in a report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.12.

Exelixis Price Performance

Shares of EXEL traded up $7.70 during trading hours on Wednesday, hitting $44.65. The stock had a trading volume of 12,913,117 shares, compared to its average volume of 2,222,003. The company's fifty day moving average is $36.80 and its two-hundred day moving average is $35.50. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $45.15. The stock has a market capitalization of $12.30 billion, a price-to-earnings ratio of 25.23, a P/E/G ratio of 1.13 and a beta of 0.25.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Transactions at Exelixis

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the transaction, the director now owns 356,605 shares in the company, valued at $13,479,669. This represents a 2.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Dana Aftab sold 1,508 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the transaction, the executive vice president now owns 693,181 shares in the company, valued at approximately $27,034,059. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 141,851 shares of company stock valued at $5,236,046. 2.82% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.